IL2 and neoplasm: However, before the development of multiple TKIs, interleukin-2(IL-2) and interferon-alfa(IFN-a) based immunotherapy is the only treatment that has been shown to improve survival in metastatic RCC(mRCC) [4, 5], which emphasizes the importance of host immunity in anti-tumor treatments.